Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.
about
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemiaEpigenetic regulators and their impact on therapy in acute myeloid leukemiaGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaCIViC databaseThe prognostic and functional role of microRNAs in acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcriptsHigh expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemiaCombined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology GroupMolecular signatures in acute myeloid leukemia.Prognostic relevance of Wilms tumor 1 (WT1) gene Exon 7 mutations in-patient with cytogenetically normal acute myeloid leukemiaSingle nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinomaMutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemiaAssociation between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese populationClinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutationsDynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapyWT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesTargeting EZH2 and PRC2 dependence as novel anticancer therapy.Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLWT1 mutations in T-ALLInteractive diagnostics in the indication to allogeneic SCT in AML.Pharmacogenomics in acute myeloid leukemia.Molecular diagnosis of acute myeloid leukemia.Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.Molecular markers in acute myeloid leukaemia.Acute myeloid leukemia with normal cytogenetics.Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?
P2860
Q26744111-9009DAD5-818F-43B0-B14D-6AEBAE27F6ABQ26765402-163B03D1-13DD-42AD-AEE3-857CCA77E2CFQ26796514-C3D9F577-3B40-4B15-93A1-E29FB2D12E80Q26998811-BD2B331A-83CA-4E98-9E4A-D3F6A3ED568FQ27612411-98CDDDF3-2256-4484-9D2E-75C7833203E4Q27693865-54B70511-BEFF-4403-B177-3148FC336C0DQ27851839-7BF9E533-51B2-4C35-8749-1BE0F60318FAQ27853004-922DD086-E119-4E0F-B0CF-AB07DFB57CC7Q28259425-A734C78F-2931-49EF-BF08-FFADB1A66581Q33623126-F2E7CB48-64A0-4C40-9E3E-8D148D46D692Q33647411-7DE0564A-D859-48A4-8021-1240D225C062Q33722630-2DFDE895-0A3A-4FA4-8CEE-387C9E04B31DQ33886181-CC79AF22-F9A6-43C2-85CA-CAC4889DE514Q33897586-B640D8AB-F83F-4536-BD30-83233A1BA425Q34022415-E54118BB-5051-4AA9-A8BB-4D7C4CA6C096Q34052581-A719C41B-ADF0-4FE0-9D05-95B4A2097E13Q34052614-EC821B6C-8A45-41EE-A27C-691985AB3837Q34079458-5E2241D8-A944-4033-ACDD-D73D7CD0F198Q34403639-B0F2516B-3ABF-4523-BBB0-9C7881BF5F3BQ34569014-702C288C-74EB-4FD9-9D14-25664CD06947Q34618828-FCBDA801-BA17-458E-A553-F9A45B51E3B4Q34876762-E225B388-CCCE-47EF-A386-93E64C5CFB2CQ35048217-2B888F54-A521-46E9-9617-AD41ED0ABFDBQ35095712-B24A05C9-F9CF-45F4-93A3-76BD744D8123Q35265946-98170CAB-1E23-44FD-9595-3BDA0C16B590Q35585976-AC672276-B694-4AE9-8495-13E112D7FD4BQ35666497-88231B52-906D-4B75-A7DA-43BBF0F765F6Q35723764-E6C0ACE2-9076-4CA4-A877-EAF454D9AEA6Q36065836-6DD55018-122F-4060-ACAD-418CA7EA9421Q36198150-75EC8BEA-D32E-47BE-985A-70B94CC150EFQ36445523-5A18F227-FB96-4A60-BDFA-E695FC3B2837Q36797201-5C130211-528C-4A3A-B8ED-AE774757A93CQ37291631-33A0D687-800A-4196-B84B-FD54CB001F78Q37442649-B737F147-72A7-4F8C-860E-F371BDDF4AE2Q37627876-1DDA6F92-2C2E-422D-87AB-58358C13723CQ37809866-98605600-1915-46B4-9B33-63E5921736AEQ37954583-019DC399-EB97-4999-85C5-3B632328D43FQ38026007-19F6290A-DD82-4435-ABF6-31292C4A78DEQ38027047-A0878A25-1CA3-4593-B8B6-AD9A0373F27CQ38044773-FE4AC40C-34EB-44F3-B8A2-593208E56B50
P2860
Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@ast
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@en
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@nl
type
label
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@ast
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@en
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@nl
prefLabel
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@ast
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@en
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@nl
P2093
P921
P356
P1476
Mutation of the Wilms' tumor 1 ...... Adult Leukaemia Working Party.
@en
P2093
Alan Burnett
Christopher Allen
Claire Green
David Linch
Dominique Bonnet
Hilmar Quentmeier
Ioannis Kakkas
Jane Stevens
Karin Summers
Priya Virappane
P304
P356
10.1200/JCO.2008.16.0333
P407
P577
2008-11-20T00:00:00Z